Diligence memo · auto-generated · as of July 2, 2026
Ngm Biopharmaceuticals Inc
Ngm Biopharmaceuticals Inc looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Ngm Biopharmaceuticals Inc operates in Biotechnology, based in SOUTH SAN FRANCISCO.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Ngm Biopharmaceuticals Inc has raised $341M in disclosed capital across 10 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $106M on 2015-03-20.
Most recent recorded round closed around 2015-03-20.
Valuation (modeled)modeled
Provath models Ngm Biopharmaceuticals Inc at approximately $4.4B (range $481M–$9.6B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.00× the median modeled value of Series D+ Biotechnology companies in 2013–2015 (7 peers) — value vs value, same stage and era. Within the normal band (100% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 10 months.
Last raise 11.3 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 5.1× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 99% of Biotechnology peers (4293 compared).
Modeled value ranks above 99% of those peers.
Closest niche peers: Adaptive Biotechnologies Corp, Aerie Pharmaceuticals Inc, Editas Medicine, Inc., Adaptimmune Ltd, Sequenom Inc.
Peoplefiled
18 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.